ECM
MDGL icon

Everence Capital Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Everence Capital Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$283K Hold
540
– – 0.02% 596
2025
Q4 		$314K Hold
540
– – 0.02% 565
2025
Q3 		$248K Buy
+540
New +$201K 0.01% 685

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Everence Capital Management's MDGL Position: Q1 2026 in Review

Everence Capital Management held its Madrigal Pharmaceuticals (MDGL) position steady in Q1 2026 at 540 shares worth $283K. The position accounts for 0.02% of the portfolio, ranked #596.

Everence Capital Management first reported a position in MDGL in Q3 2025 and has held it in 3 quarters since. The position peaked at $314K in Q4 2025. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • Everence Capital Management held 540 shares of Madrigal Pharmaceuticals worth $283K as of Q1 2026.
  • Everence Capital Management left its Madrigal Pharmaceuticals share count unchanged in Q1 2026.
  • Madrigal Pharmaceuticals made up 0.02% of Everence Capital Management's portfolio in Q1 2026, its #596 holding.
  • Everence Capital Management first reported a position in Madrigal Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Everence Capital Management's Madrigal Pharmaceuticals position peaked at $314K in Q4 2025.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Everence Capital Management's 13F filing for Q1 2026, filed 28 Apr 2026.